Document Detail

A cohort study of therapeutic prescriptions after the end of phytotherapy drug reimbursement by French Social Security.
MedLine Citation:
PMID:  23208799     Owner:  NLM     Status:  Publisher    
PURPOSE: The reimbursement of phytotherapy drugs for the treatment of mild anxiety and insomnia ended in March 2006 in France. The aim of this study is to investigate the short-term impact of stopping phytotherapy reimbursement. METHODS: We monitored the prescriptions of 27 422 patients who received hypnotic and sedative phytotherapy drug treatment at least once in the 12 months preceding the end of reimbursement and made contact with their prescribing physician at least once in the following 12 months. A control cohort was recruited from patients fulfilling the same inclusion criteria in the 24 months before de-reimbursement and their prescriptions in the following 12 months were monitored. The impact of the end of reimbursement is estimated comparing prescription switches in these cohorts. RESULTS: Before the end of reimbursement, 7684 (28%) patients being prescribed delisted phytotherapy drugs had the relevant drug marketing authorization approval (DMAA) indications. Co-prescriptions of hypnotic and sedative drugs concerned 40% of patients. Of the 4646 DMAA patients exclusively prescribed phytotherapy, 640 (14%) switched to hypnotic or sedative drugs only after the end of reimbursement, 3266 (70%) stopped all treatments and 740 (16%) carried on with a non-reimbursed phytotherapy prescription. When compared to the control cohort, patients exposed to de-reimbursement were more likely to switch to psychotropic drugs (OR = 1.46). CONCLUSIONS: Ending the reimbursement of common drugs on the basis of insufficient evidence regarding their effectiveness or the low level of severity of their target pathologies should be accompanied by information or advice to prescribing health care actors. Copyright © 2012 John Wiley & Sons, Ltd.
Lionel Riou França; Chrystelle Vidal; Nadia Bourechak; Philippe Le Jeunne; Geoffroy Sainte-Claire Deville; Jacques Massol
Related Documents :
24554929 - A drinkable formulation of alendronate: potential to increase compliance and decrease u...
6313379 - Volume of distribution terms for a drug (ceftriaxone) exhibiting concentration-dependen...
23810019 - Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a mul...
19707449 - Biological drugs targeting the immune response in the therapy of psoriasis.
24676179 - Patterns of antimicrobial therapy in acute tonsillitis: a cross-sectional hospital-base...
23329709 - Drug-induced immune thrombocytopenia due to moxifloxacin.
12176009 - Total mercury in muscle tissue of five shark species from brazilian offshore waters: ef...
12613399 - Effect of ursodeoxycholic acid on hydrogen peroxide induced lipid peroxidation in sheep...
15274669 - Economic analysis of strategies in the prevention of non-steroidal anti-inflammatory dr...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-12-4
Journal Detail:
Title:  Pharmacoepidemiology and drug safety     Volume:  -     ISSN:  1099-1557     ISO Abbreviation:  Pharmacoepidemiol Drug Saf     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-4     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9208369     Medline TA:  Pharmacoepidemiol Drug Saf     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 John Wiley & Sons, Ltd.
Phisquare Institute - Fondation Transplantation, Paris, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Reproductive and Neurobehavioral Effects of Brilliant Blue FCF in Mice.
Next Document:  Combinatorial Displacement of DNA Strands: Application to Matrix Multiplication and Weighted Sums.